We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

137 hedge funds and large institutions have $1.36B invested in Krystal Biotech in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more call options, than puts

Call options by funds: $9.2M | Put options by funds: $3.87M

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

1% more funds holding

Funds holding: 135 → 137 (+2)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% less capital invested

Capital invested by funds: $1.37B → $1.36B (-$961K)

0.63% less ownership

Funds ownership: 81.7% → 81.07% (-0.63%)

12% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 52

Holders
137
Holders Change
+2
Holders Change %
+1.48%
% of All Funds
2.31%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
19
Increased
46
Reduced
52
Closed
15
Calls
$9.2M
Puts
$3.87M
Net Calls
+$5.32M
Net Calls Change
+$2.9M

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$14.3M
2
RCMNY
Rubric Capital Management (New York)
New York
+$5.76M
3
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
+$5.53M
4
RG
Redmile Group
California
+$5.15M
5
ACA
Avoro Capital Advisors
New York
+$4.35M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.08M
2
FLAM
First Light Asset Management
Minnesota
-$7.61M
3
SCM
Soleus Capital Management
Connecticut
-$4.66M
4
Jennison Associates
Jennison Associates
New York
-$4.54M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$3.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Handelsbanken Fonder
26
Handelsbanken Fonder
Sweden
$7.41M +$180K +2,900 +3%
SST
27
S Squared Technology
New York
$7.11M – – –
SCM
28
Silverarc Capital Management
Massachusetts
$6.91M +$3.66M +58,788 +126%
RCMNY
29
Rubric Capital Management (New York)
New York
$6.08M +$5.76M +92,609 New
N
30
Nuveen
North Carolina
$5.6M +$68.2K +1,097 +1%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$5.27M -$413K -6,632 -8%
Morgan Stanley
32
Morgan Stanley
New York
$5.21M +$459K +7,374 +10%
ACM
33
ACT Capital Management
Pennsylvania
$3.87M – – –
Allianz Asset Management
34
Allianz Asset Management
Germany
$3.79M +$1.73M +27,809 +93%
Verition Fund Management
35
Verition Fund Management
Connecticut
$3.59M +$1.47M +23,578 +76%
IHAM
36
Integral Health Asset Management
New York
$3.43M +$3.25M +52,184 New
Carson Wealth (CWM LLC)
37
Carson Wealth (CWM LLC)
Nebraska
$2.96M -$445K -7,159 -14%
Swiss National Bank
38
Swiss National Bank
Switzerland
$2.71M – – –
Bank of America
39
Bank of America
North Carolina
$2.54M -$240K -3,858 -9%
State of New Jersey Common Pension Fund D
40
State of New Jersey Common Pension Fund D
New Jersey
$2.53M +$2.39M +38,478 New
Citigroup
41
Citigroup
New York
$2.43M +$1.36M +21,785 +143%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$2.18M -$1.67M -26,820 -45%
HWAM
43
Hennion & Walsh Asset Management
New Jersey
$2.17M +$599K +9,625 +41%
EI
44
EAM Investors
California
$2.01M -$202K -3,248 -10%
ACM
45
Atika Capital Management
New York
$1.97M +$1.87M +30,000 New
DekaBank Deutsche Girozentrale
46
DekaBank Deutsche Girozentrale
Germany
$1.92M +$311K +5,000 +20%
MOACM
47
Mutual of America Capital Management
New York
$1.89M -$13.4K -216 -0.7%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.87M +$289K +4,646 +19%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$1.8M +$21.6K +348 +1%
Victory Capital Management
50
Victory Capital Management
Texas
$1.79M +$1.7M +27,348 New
1
2
3 4 5

KRYS Hedge Fund Activity: Q2 2022 in Review

137 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2022, worth a combined $1.36B — down 0.07% from $1.37B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KRYS positions and 15 closed out — a net gain of 4 holders — while 46 added to existing stakes and 52 trimmed.

The largest buyer was Frazier Life Sciences Management, adding an estimated $14.3M. The largest seller was Point72 Asset Management, cutting an estimated $9.08M.

  • 137 institutional investors held Krystal Biotech (KRYS) as of Q2 2022, up from 135 in Q1 2022.
  • Funds reported $1.36B of Krystal Biotech stock for Q2 2022, down 0.07% quarter-over-quarter.
  • 19 funds opened new Krystal Biotech positions in Q2 2022 and 15 closed out, a net change of +4 holders.
  • The largest Krystal Biotech buyer in Q2 2022 was Frazier Life Sciences Management, an estimated $14.3M added.
  • The largest Krystal Biotech seller in Q2 2022 was Point72 Asset Management, an estimated $9.08M sold.

Based on aggregated 13F filings for Q2 2022.